Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study

Several targeted agents including multi-tyrosine kinase inhibitors (mTKIs) and immunotherapy (IO) agents have been approved for use beyond the frontline setting in patients with advanced hepatocellular carcinoma (HCC). Due to lack of prospective head-to-head comparative trials, there is no standardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeed, Anwaar, Hildebrand, Hannah, Park, Robin, Al-Jumayli, Mohammed, Abbasi, Saqib, Melancon, Tina, Saeed, Azhar, Al-Rajabi, Raed, Kasi, Anup, Baranda, Joaquina, Williamson, Stephen, Sun, Weijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563439/
https://www.ncbi.nlm.nih.gov/pubmed/32824968
http://dx.doi.org/10.3390/jcm9092682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563439/
https://www.ncbi.nlm.nih.gov/pubmed/32824968
http://dx.doi.org/10.3390/jcm9092682

Ejemplares similares